Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis.
暂无分享,去创建一个
[1] H. Huland,et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. , 1990, The Journal of urology.
[2] H. Huland,et al. Urindiagnostik oberflächlicher Harnblasentumoren durch Zytologie, Immunzytologie und Flowzytometrie , 1988 .
[3] V. Laudone,et al. An overview of intravesical therapy for superficial bladder tumors. , 1987, The Journal of urology.
[4] H. Huland,et al. Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology. , 1987, The Journal of urology.
[5] H. Huland,et al. Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells. , 1987, The Journal of urology.
[6] H. Huland,et al. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. , 1984, The Journal of urology.
[7] W Lutzeyer,et al. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.
[8] J. Rowe,et al. The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. , 1978, The Journal of urology.
[9] R. Barnes,et al. Changes in grade and stage of recurrent bladder tumors. , 1977, The Journal of urology.
[10] A. Althausen,et al. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. , 1976, The Journal of urology.
[11] R. Schade,et al. The association of urothelial atypism with neoplasia: its importance in treatment and prognosis. , 1973, The Journal of urology.